GSK's ViiV, under threat from Gilead-Merck collab, eyes 'ultra-long-acting' HIV drugs with Halozyme deal Bayer lands FDA approval for OTC allergy nasal spray Astepro Ena Respiratory raises $24M to trial COVID-19 nasal spray Boosted by COVID-19, Stevanato seeks $100M IPO to invest in biologics and vaccine delivery Satsuma heads back to phase 3 after tweaking delivery device Featured Story | By Angus Liu With competition in the HIV field heating up, drugmakers are continually looking to improve treatment regimens by reducing dosing requirements. Now, GlaxoSmithKline has penned a new deal with Halozyme as it hopes to safeguard its lead on that latter front amid expected competition from a formidable tie-up between Gilead Sciences and Merck & Co. read more |
| |
|---|
|
| | Webinar: COVID-19 Virus Sequencing for Drug Development Wednesday, July 28 | 10:30am ET / 7:30am PT As new COVID-19 variants continue to emerge, virus sequencing will play critical and ongoing role in drug and vaccine development. This webinar will connect insights from population surveillance to potential solutions for drug developers, outline approaches to COVID-19 virus sequencing and more. Register Now. |
Top Stories By Nick Paul Taylor The FDA has approved Bayer’s Astepro allergy nasal spray for over-the-counter use. Bayer said the product is the first steroid-free antihistamine nasal spray for allergy relief to be authorized for OTC use in the U.S. read more By Nick Paul Taylor Ena Respiratory has raised up to $32 million Australian dollars ($24 million) to fund clinical development of a nasal spray designed to prevent COVID-19. The product, INNA-051, delivers a TLR2/6 agonist to upregulate innate immune responses in airway epithelial cells and thereby help suppress the coronavirus. read more By Nick Paul Taylor Stevanato has filed to raise up to $100 million in an IPO. The offering is intended to equip Stevanato to invest in its biologics and vaccine delivery capabilities after a year in which COVID-19 caused sales to soar. read more By Nick Paul Taylor Satsuma Pharmaceuticals has presented phase 1 data on its second-generation nasal delivery device. The readout positions Satsuma to start a phase 3 clinical trial designed to enable it to bounce back from a pivotal failure last year. read more Resources Sponsored by: Clinical Ink For faster deployment, improved patient engagement, and better-quality data — go where your patients are. GO BYOD with Lunexis™ from Clinical Ink. Sponsored by: BBK Worldwide Create a more diverse and inclusive clinical trial enrollment and engagement environment by learning the barriers to participation and the strategies to overcome them. Sponsored by: Thermo Fisher Scientific Autologous cell and gene therapy workflows involve isolating cells from an individual, engineering the cells, expanding and concentrating them, and infusing them back into the patient. Optimized automation of certain steps of the workflow may decrease hands-on time and the cost of the cell manufacturing process. Sponsored By: Veeva Learn how to develop a standards program that has your full team’s buy-in and improves the efficiency and quality of your clinical trials. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process intesification Sponsored By: August Bioservices How has COVID-19 impacted CRO/CDMO customer (dis)satisfaction and outsourcing decisions for pharma and biotech companies in 2021 and beyond? Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored By: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. Sponsored By: Within3 We enable virtual work — offering over-time sessions where participants are more focused, insights are more diverse and business goals are met. Sponsored by: Catalent Discover the current state of patient-focused dose design through clinical evidence, real-world case studies and patient preference-driven drug design solutions that can help develop better treatments and successful real-world outcomes. Sponsored by: Catalent This eBook features insights from experts in the industry on patient-centric drug development challenges and strategies on advancing drug design and development effectively. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Diversity, Equity & Inclusion Week August 9-11, 2021 | Virtual Event Medical Affairs Strategic Summit (MASS) September 13-15, 2021 | New Brunswick, NJ Promotional Review Committee Compliance & Best Practices September 13-15, 2021 | New Brunswick, NJ Clinical Quality Oversight Forum September 27-29, 2021 | Philadelphia, PA Digital Pharma East September 28-30, 2021 | Pennsylvania Convention Center, Philadelphia | October 5-8, 2021 | Virtual Event Fierce Pharma Marketing Awards September 29, 2021 | Philadelphia, PA | 